Amotiv Limited (AOV : TSX)
Common Stock
Follow AOV
AOV
Amotiv Limited
WealthAwesomePerformance
1 Day
+1.58%
1 Week
+2.47%
1 Month
+7.11%
YTD
+96.28%
Key Statistics
Market Cap
$576.83M
52W High
$11.89
52W Low
$5.66
P/E Ratio
-
50 Day MA
$5.81
200 Day MA
$5.36
Beta
0.49
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 11/9/2026 | $11.40 | $11.89 | $11.37 | $11.60 | $11.60 | 146,264 |
| 11/6/2026 | $11.81 | $11.86 | $11.27 | $11.42 | $11.42 | 74,637 |
| 11/5/2026 | $11.84 | $11.86 | $11.29 | $11.56 | $11.56 | 162,847 |
| 11/4/2026 | $11.31 | $11.31 | $10.90 | $11.30 | $11.30 | 66,643 |
| 11/3/2026 | $11.32 | $11.33 | $11.18 | $11.26 | $11.26 | 28,638 |
| 11/2/2026 | $11.34 | $11.44 | $11.26 | $11.32 | $11.32 | 71,775 |
| 10/30/2026 | $11.34 | $11.41 | $11.25 | $11.27 | $11.27 | 15,766 |
| 10/29/2026 | $11.34 | $11.43 | $11.28 | $11.40 | $11.40 | 62,809 |
| 10/28/2026 | $11.28 | $11.41 | $11.23 | $11.31 | $11.31 | 43,954 |
| 10/27/2026 | $11.63 | $11.66 | $11.21 | $11.28 | $11.28 | 73,324 |
Analyst Price Targets
Based on analyst covering AOV · as of Sep 17, 2026
Wall Street analysts forecast AOV stock price to fall 38.0% over the next 12 months.
Consensus
BearishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.19
-38.0% Upside
Current Price
C$11.60
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on AOV's historical volatility
30-Day Vol
23.1%
Annualized
90-Day Vol
26.1%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$13.87
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$12.31 | C$11.37 – C$13.33 |
| 60 trading days | C$13.07 | C$11.67 – C$14.62 |
| 90 trading days | C$13.87 | C$12.08 – C$15.92 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Amotiv Limited
Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.
Financials
- Revenue (TTM)
- $332.21M
- EBITDA
- $49.78M
- Profit Margin
- -5.25%
- ROE (TTM)
- -2.21%
- EPS (Diluted)
- -0.16
- Book Value
- 7.53
Classification
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Free newsletter
The Tuesday Stock Pick
One Canadian stock and the case for it
- The name with the biggest gap to analyst targets
- The chart, insider buying and what is driving it
- A plain-English bottom line, no hype
Explore More
Common Questions About AOV
Market movers
Recent TSX movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| PNC-A | Postmedia Network Canada Corp | $0.14 | +38.10% |
| GFR | Greenfire Resources Ltd. | $10.94 | +37.96% |
| ADCO | Adcore Inc | $0.17 | +21.43% |
| DND | Dye & Durham Ltd | $1.96 | +20.99% |
| COPR | Coppernico Metals Inc. | $0.38 | +20.97% |
| ELEF | Silver Elephant Mining Corp | $0.32 | +20.75% |
| FT | Fortune Minerals Limited | $0.09 | +20.00% |
| SAM | Starcore International Mines Ltd | $0.32 | +18.52% |